[PMID]: | 29185099 |
[Au] Autor: | Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U |
[Ad] Endereço: | Department of Ophthalmology, Campus Virchow-Klinikum, Charité - University Medicine Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany. sibylle.winterhalter@charite.de. |
[Ti] Título: | Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. |
[So] Source: | Graefes Arch Clin Exp Ophthalmol;256(2):267-279, 2018 Feb. |
[Is] ISSN: | 1435-702X |
[Cp] País de publicação: | Germany |
[La] Idioma: | eng |
[Ab] Resumo: | PURPOSE: To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting. METHODS: A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN). Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and intraocular pressure (IOP) were compared between the two therapy groups after 1, 3 and 6 months. RESULTS: BRVO patients treated with DEX achieved a statistically significant gain in BCVA measured in logMAR after 1 month (mean gain, 95% CI: 0.21, 0.08-0.34, p = 0.001), 3 months (0.16, 0.03-0.28, p = 0.012) and 6 months (0.19, 0.07-0.32, p = 0.002), whereas patients treated with IVR showed a statistically significant BCVA gain in month 3 (mean improvement, 95% CI: 0.13, 0.01-0.26, p = 0.039) and month 6 (0.16, 0.03-0.29, p = 0.018). BCVA in CRVO patients with DEX worsened slightly at month 6 (mean worsening, 95% CI: -0.08, -0.24 to 0.08, p = 0.305), while IVR treated-patients achieved a statistically significant BCVA gain at 3 months (mean improvement, 95% CI: 0.14, 0.02-0.25, p = 0.021). Both therapies were accompanied by statistically significant CRT reductions of 150 to 200 µm (median). Adverse events reported were predictable and limited. CONCLUSIONS: In a clinical setting, comparable improvement in BCVA and CRT were observed after DEX and IVR injections for treatment of BRVO. CRVO patients showed greater benefit with IVR. |
[Mh] Termos MeSH primário: |
Dexametasona/administração & dosagem Edema Macular/tratamento farmacológico Ranibizumab/administração & dosagem Oclusão da Veia Retiniana/tratamento farmacológico Acuidade Visual
|
[Mh] Termos MeSH secundário: |
Idoso Inibidores da Angiogênese/administração & dosagem Relação Dose-Resposta a Droga Implantes de Medicamento Quimioterapia Combinada Feminino Seguimentos Glucocorticoides/administração & dosagem Seres Humanos Injeções Intravítreas Edema Macular/diagnóstico Edema Macular/etiologia Masculino Oclusão da Veia Retiniana/complicações Oclusão da Veia Retiniana/diagnóstico Estudos Retrospectivos Fatores de Tempo Tomografia de Coerência Óptica Resultado do Tratamento Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE; OBSERVATIONAL STUDY |
[Nm] Nome de substância:
| 0 (Angiogenesis Inhibitors); 0 (Drug Implants); 0 (Glucocorticoids); 0 (Vascular Endothelial Growth Factor A); 7S5I7G3JQL (Dexamethasone); ZL1R02VT79 (Ranibizumab) |
[Em] Mês de entrada: | 1802 |
[Cu] Atualização por classe: | 180214 |
[Lr] Data última revisão:
| 180214 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 171130 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1007/s00417-017-3852-1 |
|
|